We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRP Level Is Independent Risk Factor for Stroke

By Biotechdaily staff writers
Posted on 04 Jul 2003
A recent study has shown that the level of C-reactive protein (CRP) in the blood is an independent risk factor for stroke regardless of the thickness of carotid artery walls, and that people with thicker artery walls are at greater risk. More...


Investigators at the University of Vermont (Burlington, USA; www.uvm.edu) determined the CRP level in blood samples from 5,417 men and women age 65 or older participating in the US Cardiovascular Health Study, a prospective trial investigating risk factors for cardiovascular disease in the elderly. In addition, each patient was examined by ultrasound to determine the thickness of the walls of the carotid artery.

The results, published June 23, 2003, in the online edition of Circulation, showed that subjects in the highest quartile of CRP levels were 60% percent more likely to have a stroke, compared to those with the lowest CRP levels. People in the second quartile were 19% more likely to have a stroke, while those in the third CRP quartile were 5% more likely to have a stroke than those with the lowest levels. Among people with the thinnest carotid walls, there was no significant association between CRP and stroke, but among those people with thicker carotid walls, there was a significant association between CRP and stroke.

"We found that while C-reactive protein is an independent risk factor for stroke, it is even more closely related to stroke in people with thicker artery walls than in people with thinner walls,” explained senior author Dr. Mary Cushman, an associate professor of medicine at the University of Vermont. "This raises the possibility that higher CRP is associated with more active or unstable plaque that is more likely to rupture and cause a stroke. The findings add to the growing body of evidence that supports using CRP measurements in assessing certain individuals' global cardiovascular disease risk.”



Related Links:
University of Vermont

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.